Curasight

Curasight is a clinical-stage biotech company with a mission to improve cancer care through a first-in-class theranostics platform targeting the urokinase-type plasminogen activator receptor (uPAR), a key driver of tumor aggressiveness. Its core achievement is the clinical validation of its uTRACE® diagnostic across ~450 patients in eight solid tumor types, which de-risks the parallel development of its therapeutic counterpart, uTREAT®. The company's strategy is to leverage this 'pipeline-in-a-drug' platform across multiple aggressive cancers, initially focusing on brain and prostate cancer, while seeking partners for later-stage development and commercialization.

A uPAR-targeted theranostics platform combining uTRACE® (diagnostic PET imaging) and uTREAT® (therapeutic radioligand therapy) based on the same targeting ligand for precise cancer diagnosis and treatment.

Curasight competes in the radiopharmaceutical space against large players (Novartis, Bayer) and biotechs, but its first-in-class focus on the uPAR target provides differentiation. Its clinically validated uTRACE® diagnostic creates a significant moat and de-risking advantage not commonly held by early-stage RLT companies.